热门资讯> 正文
因监管不确定性，贝尔德的Neurogene评级下调至中立
2025-05-16 23:18
- Neurogene (NASDAQ:NGNE) was downgraded to Neutral from Outperform at Baird, citing increasing regulatory uncertainty and a higher approval bar at the FDA under new leadership.
- The analysts at Baird said that despite the stock rebound since April, they believe the FDA's bar for approval is indeed moving higher, as former head of Center for Biologics Evaluation and Research, Peter Marks, has been replaced by a far more data-driven Vinay Prasad.
- Refering to Taysha Gene Therapies's (TSHA) recent data, the analysts said, "The data to date for the Rett syndrome gene therapies from NGNE and TSHA seem messy to us, and closer to Elevidys than a 'parachute'.
- Baird analysts have also cut price target for the company to $24 from previous $38.
- The stock is down 11.7% so far today.
More on Neoleukin Therapeutics
- Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401
- Neurogene GAAP EPS of -$1.08 misses by $0.02
- Top 10 Russell 2000 weekly gainers and losers as Wall Street crashes
- Seeking Alpha’s Quant Rating on Neoleukin Therapeutics
- Historical earnings data for Neoleukin Therapeutics
推荐文章
一周财经日历丨降息信号将定？下周全球央行年会成关键；小米、泡泡玛特、快手领衔港股财报潮
港股周报丨见证历史！南向资金单日疯狂买入港股359亿港元；腾讯绩后股价一度升破600港元
特朗普政府据悉考虑动用芯片法案资金来入股英特尔
美股机会日报丨“恐怖数据”符合预期，交易员下调美联储降息预期；巴菲特Q2新建仓股飙升，联合健康盘前涨超10%
银诺医药-B上市首日暴涨285%，一手赚超1万港元
投资大佬Tepper减持阿里巴巴、京东等 买入股价暴跌的联合健康
伯克希尔减持苹果股份 增持联合健康集团
8月15日外盘头条：特朗普政府洽购英特尔股份 贝森特否认推动降息 苹果重新设计Apple Watch血氧功能
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
